Differentiated drug development pipeline with innovative targets and treatment conceptsDeveloping products with high commercial potential and marketability that fulfill important, unmet medical needs
KEY DEVELOPMENT AREA
AGE-RELATED
VASCULAR DISEASES
CU03, CU06 – Macular degeneration
CU06 – Diabetic retinopathy
CU06 – Stroke / Myocardial infarction
INTRACTABLE
METABOLIC DISEASES
CU01 – Renal fibrosis
CU02 – Nonalcoholic steatohepatitis
CU06 – Inflammatory bowel disease
CANCER TARGETING /
IMMUNOTHERAPY
CU04 – AML, Solid tumor
CU05 – Solid tumor
CU06 – Immuno-oncology concomitant treatment
Innovative drug development pipeline development strategyDifferentiated R&BD for Fast New Drug Success and Profitability
BUSINESS MODEL
